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ABSTRACT
Treating breast cancer brain metastases (BCBMs) is challenging. Na+/I- symporter 
(NIS) expression in BCBMs would permit their selective targeting with radioiodide 
(131I-). We show impressive enhancement of tumor response by combining131I- with 
gemcitabine (GEM), a cytotoxic radiosensitizer. Nude mice mammary fat-pad (MFP) 
tumors and BCBMs were generated with braintropic MDA-MB-231Br cells transduced 
with bicistronically-linked NIS and firefly luciferase cDNAs. Response was monitored in 
vivo via bioluminescent imaging and NIS tumor expression.131I-/GEM therapy inhibited 
MFP tumor growth more effectively than either agent alone. BCBMs were treated 
with: high or low-dose GEM (58 or 14.5 mg/Kg×4); 131I- (1mCi or 2×0.5 mCi 7 days 
apart); and 131I-/GEM therapy. By post-injection day (PID) 25, 82-86% of controls 
and 78-83% of 131I--treated BCBM grew, whereas 17% low-dose and 36% high-dose 
GEM regressed. The latter tumors were smaller than the controls with comparable 
NIS expression (~20% of cells). High and low-dose 131I-/ GEM combinations caused 
89% and 57% tumor regression, respectively. High-dose GEM/131I- delayed tumor 
growth: tumors increased 5-fold in size by PID45 (controls by PID18). Although 
fewer than 25% of cells expressed NIS, GEM/131I- caused dramatic tumor regression 
in NIS-transduced BCBMs. This effect was synergistic, and supports the hypothesis 
that GEM radiosensitizes cells to 131I-.
INTRODUCTION
Breast cancer brain metastases (BCBMs) are 
challenging to treat, and the prognosis for affected patients 
is poor relative to that of patients with metastases elsewhere 
[1, 2]. Indeed, central nervous system (CNS) involvement 
occurs in a significant proportion of patients with triple 
negative [TN, (estrogen receptor, progesterone receptor, 
and HER2-negative)] and HER2+ metastatic subtypes. In 
general, systemic therapies are less successful in the CNS 
than at other metastatic sites. The blood-brain barrier (BBB) 
has been thought to impair the entry of cytotoxic, hormonal, 
and biological agents, providing one explanation for their 
limited activity against BCBMs. Additionally, the difficulty 
of achieving and sustaining optimal concentrations of drugs 
is likely compounded by rapid drug efflux [3]. Thus, for 
patients with BCBMs, surgical resection and radiation 
therapy continue to be the most successful therapeutic 
interventions, but are associated with debilitating 
neurological and neurocognitive deficits.
Clearly, ideal strategies would selectively target 
BCBMs without affecting the normal brain tissue. 
We measured the effectiveness of targeted internal 
radiotherapy with 131I- (radioiodide) combined with a 
radiosensitizing agent in a preclinical BCBM mouse 
model. 131I- therapy is worth testing in BCBMs because 
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the endogenous mechanism of Na+/I- symporter (NIS)–
mediated iodide (I-) transport is present in many breast 
cancer cells [4]. NIS is an intrinsic plasma membrane 
glycoprotein that mediates active I- transport in the thyroid 
and a few other tissues, including the lactating breast, 
salivary glands, stomach, and small intestine [5]. NIS 
couples the transport into the cell of one I- ion, against its 
concentration gradient, to that of two Na+ ions, down their 
concentration gradient, which is generated by the Na+/K+ 
ATPase [6, 7]. NIS-driven I- transport is the key first step 
in the biosynthesis of the thyroid hormones (T
3
 and T4). 
Clinically, the most relevant application of NIS has been 
its use in targeted intracellular delivery of high-energy 131I- 
to ablate toxic nodules and thyroid cancer metastases. A 
second key clinical application of NIS has been its use 
in thyroid imaging, which is based on translocation of 
iodide radioisotopes and pertechnetate (99mTcO4
-), another 
NIS substrate. Since NIS was identified and began to be 
characterized at the molecular level, its preclinical and 
clinical applications have expanded greatly: it is now used 
as both a reporter and a therapeutic molecule [5].
I- concentrated in maternal milk is the only 
I- available to the nursing newborn for use in the 
biosynthesis of his or her thyroid hormones, T
3
 and T4. 
The accumulation of I- in the milk is made possible by 
the functional expression of NIS in breast cells during 
lactation [8, 9]. This observation led us to discover 
that NIS is also expressed in breast cancer. NIS is 
endogenously expressed to varying degrees in over 
80% of breast cancers and, interestingly, in over 50% 
of the TN BCBMs studied by our group [4, 10]. Focal 
radioiodide uptake has been demonstrated in imaging 
studies of patients with NIS-expressing locally advanced 
or metastatic breast cancers [11, 12].
Exogenous NIS gene transfer into non-thyroid 
tumor cells has been carried out successfully in multiple 
studies reporting selective killing of these cells by NIS-
mediated 131I- accumulation [5, 13, 14]. The effectiveness 
of targeted 131I- therapy has been shown in prostate cancer, 
multiple myeloma, breast cancer and intracerebral glioma 
xenograft models [14–16].
In breast cancer, where NIS is often expressed 
endogenously, the radioablative effects of NIS-mediated 
131I- accumulation could conceivably be enhanced by 
combining 131I- with an anticancer agent that increases 
tumor cell vulnerability to the DNA-damaging effects 
of radiation. Gemcitabine (GEM) is a deoxycytidine 
analogue used in the treatment of patients with metastatic 
breast cancer. As first-line therapy, it has reported response 
rates of 12-37% [17]. The anti-tumor and radiosensitizing 
properties of GEM have been demonstrated for example 
in bladder, mucoepidermoid lung, pancreatic, head 
and neck, colon, and breast tumor cell lines [18, 19]. 
Clinically, GEM has been co-administered with external 
beam radiation therapy for pancreas, head and neck, and 
bladder cancer, as well as in BCBMs [20–23]. Thus, we 
sought to investigate the effectiveness of concurrent GEM 
with NIS-mediated 131I- therapy in an experimental BCBM 
mouse model, and obtained highly promising results [24].
RESULTS
Immunoblot analysis of transduced 
MDA-MB-231Br
NIS expression was demonstrated in MDCK and 
MDA-MB-231Br cells that were stably transduced with 
a lentiviral vector containing NIS cDNA linked via a bi-
cistronic cassette to firefly luciferase 2 (Fluc2) cDNA, 
under the CMV promoter (NIS-IRES-LUC=NIL). 
Two bands corresponding to NIS were detected in the 
transduced cells, in contrast to the complete absence of 
expression in the non-transduced MDA-MB-231Br cells 
[Figure 1A].
NIS-mediated 131I- accumulation ablates 
MDA-MB-231Br cells in a dose-dependent manner
In vitro I- uptake and bioluminescence assays were 
performed to characterize NIS and Fluc expression in 
transduced MDA-MB-231Br cells. The selected clone 
exhibited a 25-fold increase in NIS-mediated 99mTcO4
- 
uptake [Figure 1B], as compared to non-transduced cells; 
the in vitro bioluminescence (BLI) signal correlated 
linearly with the number of cells [Figure 1C]. Flow 
cytometry analysis showed that 97.5% of the transduced 
cells expressed NIS and Fluc.
Cell sensitivity to 131I- was analyzed by exposing 
cells to various doses of this radioisotope, and performing 
a clonogenic survival assay. The fraction of cells that 
survived decreased in a dose-dependent manner [Figure 
1D and 1E]. The highest dose tested (400 µCi) reduced the 
fraction of surviving cells to only 24%.
GEM cytotoxicity was evaluated in parental and 
transduced MDA-MB-231Br-NIL cells incubated for 
48 hours with doses ranging from 0.0001 to 1000 µM. 
Following treatment, cell viability was determined with 
a MTS assay. GEM treatment had a dose-dependent 
effect on cell survival [Figure 1F]. Maximal response 
was reached with 1 mM, which caused a 56% decrease in 
cell survival. The concentration of the drug yielding half-
maximal response (EC50) was estimated to be 1.44 ± 0.76 
µM for the transduced cells and 0.588 ± 0.065 µM for the 
parental cells.
MFPs and BCBMs actively transport 123I-
In vivo 123I- uptake measurements in mice with MFP 
tumors showed peak uptake by these tumors at 2 hours of 
16.8 ± 8.2 % ID/g, decreasing to 10.6 ± 3.0 and 8.2 ± 4.4 
%ID/g at 4 and 6 hours respectively. These levels exceed the 
stomach at the early timepoints but are comparable to the 
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Figure 1: Cell characterization and cytotoxicity studies. MDA-MB-231Br cells were stably transduced with a lentiviral vector 
containing human NIS cDNA linked via a bicistronic construct to the firefly luciferase 2 cDNA (NIS-IRES-luc2, NIL), driven by a CMV 
promoter. A. Immunoblot analysis of membrane fractions (15 μg) derived from transduced control MDCK cells, MDA-MB-231Br-NIL 
(lanes 1 and 2) and non-transduced MDA-MB-231Br (lane 3). Distinct bands corresponding to NIS protein are seen in lanes 1 and 2, 
but completely absent in 3. B. Functional expression of NIS was measured by quantitating 99mTcO4- uptake in single-cell-derived clonal 
populations. C. Functional expression of luciferase was measured using in vitro bioluminescence. Cell number correlates linearly with in 
vitro bioluminescence (r2 = 0.995). D–E. In vitro cytotoxicity in MDA-MB-231Br-NIL cells exposed to increasing doses of 131I- (0, 40, 200, 
or 400 µCi) for 7 hours. [D] Representative photographs of a131I- clonogenic assay and [E] surviving fraction or colony-forming efficiency 
determined 10 to 14 days later (mean ± SD; * p < 0.05; **** p < 0.0001 post hoc Tukey’s multiple comparisons test). F. Dose-dependent 
effect of gemcitabine (GEM) on cell survival. Cell viability determined by MTS assay after a 48-hour incubation of 0.0001 to 1000µM 
GEM relative to HBSS-treated control. The concentration of the drug yielding half-maximal response (EC50) was estimated to be 1.44 ± 
0.76 µM for the transduced cells and 0.588 ± 0.065 µM for the parental cells.
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peak uptake recorded at 6 hours of 9.9 ± 4.2 %ID/g. Other 
organs showed much lower accumulation (1.00 %ID/g or 
less at all timepoints). Notably, normal brain tissue had the 
lowest signal of all organs studied, peaking at 6 hours of 
0.16 % ID/g compared to 0.08 %ID/g at 2 hours [Figure 
2A]. In experiments with stereotactic-generated BCBMs, 
123I- uptake at 1 hour was approximately 13.6 times greater 
in these mice (1.81 ± 1.53 %ID/g) than in control animals 
(0.133 ± 0.047 %ID/g) [Figure 2B].
Immunoblot analysis of tissue samples derived from 
MFP and BCBMs demonstrated NIS protein expression: 
a predominant band corresponding to the mature 
polypeptide and a band that migrates faster, corresponding 
to the partially glycosylated polypeptide [Figure 2C]. 
Consistent with the immunoblot, fewer cells expressing 
NIS were observed by IHC in BCBMs than in MFPs. 
Similarly, NIS expression was demonstrated in a human 
TN breast cancer by immunoblot and IHC [Figure 2D] 
as well as in a human TN BCBM [Figure 2E]. A small 
portion of the former was freshly implanted orthotopically 
into a NOD SCID mouse (PDOX). Archival tissue section 
of a second passage xenograft showed comparable strong 
NIS expression.
The combined GEM/131I- treatment is more 
effective than either treatment alone
In mice bearing orthotopic MFP tumors, five 
treatments were investigated beginning ten days post-
implantation (PI). Exponential tumor growth occurred 
in untreated mice and all were sacrificed by day 32. 
Treatment with 1 mCi 131I- alone (as a single dose or 
divided into 2 x 0.5 mCi doses) caused similar growth 
inhibition with both dosing schemes, as measured by BLI 
over a 50-day period [Figure 3]. A significant effect of 
GEM on tumor growth was also observed with 4 doses 
of 58 mg/kg (174 mg/m2) every 3 days. Remarkably, 
combined treatments of GEM 58 mg/kg × 4 with 1mCi 
131I- or 2 × 0.5 mCi 131I- resulted in the greatest decrease in 
BLI. No significant weight loss, gait disturbances, or other 
morbidities were observed with the treatments.
Therapeutic effectiveness was also studied in mice 
with stereotactically generated BCBMs. A representative 
example of tumor response for each treatment regimen 
is depicted in Figure 4A-D. Sham or saline-treated mice 
had the largest brain tumors, consistent with the BLI 
measurements and steady growth [Figure 4A and 5A]. 
The second-largest tumors were those treated with 131I- 
only, indicating limited therapeutic effect [Figure 4B and 
5B]. The latter were followed by those treated with GEM 
alone [Figure 4C and 5C], and the smallest tumors of all 
occurred in the mice that received dual therapy [Figure 
4D and 5D].
NIS expression was remarkably sparse at PID 
11, being found in only 5% of tumor cells [Figure 2C]. 
Later, at PID25, the proportion of NIS-expressing cells 
in exponentially growing tumors increased, but exhibited 
regional heterogeneity [Figure 5A]. Specifically, the 
intracerebral portion of untreated BCBMs exhibited 
up to 20% NIS-positive cells with noticeably fewer 
immunoreactive cells in tumor areas extending above the 
surface of the brain, a finding reminiscent of observations 
in MFP xenografts.
Tumor response in each mouse was classified using 
the criterion of a 2-fold change in BLI over the course of 
treatment through PID25, the timepoint at which treated 
tumors reached a nadir. BCBMs exhibiting a 2-fold 
increase in BLI were classified as growing, tumors with a 
2-fold decrease as regressing, and all others as exhibiting 
stable disease. The vast majority of brain metastases in the 
control group (82-86%) grew [Figure 6A and 6B]. Mice 
treated with 131I- alone showed little or no tumor response: 
tumors grew in 78-83% of cases, and regression occurred 
in only 11% of tumors that received a single radioisotope 
dose [Figure 6B] and 17% of tumors that received divided 
radioisotope doses [Figure 6A]. By contrast, tumors grew 
in only 27% of mice under the higher-GEM regimen, 
whereas 72% of mice exhibited stable disease or tumor 
regression (36% and 36% respectively) [Figure 6B]. Low-
dose GEM alone was associated with growth in 66% of 
BCBMs animals, and induced far less tumor regression 
or stability [Figure 6A]. Strikingly, the dual therapy 
(GEM/131I-) had a significant effect on BCBMs. No tumors 
grew under the high-dose combination therapy, only 11% 
exhibited stable disease, and 89% regressed [Figure 6B]. 
The low-dose dual therapy further illustrated the synergism 
between GEM and 131I-, given the limited effect of each 
of these drugs alone. The low-dose dual therapy induced 
tumor regression in 57% of mice, and an additional 29% 
showed stable disease [Figure 6A]. ANOVA analysis 
depicts the differences in BLI of surviving mice on PID25 
in each of the groups [Figure 6C–6D].
A time-to-progression analysis was carried out for 
mice treated with high-dose GEM [Figure 7]. Time to 
progression was defined as the time it took for the BLI 
value to increase 5 times its baseline fluorescence at 
PID10. Nearly all mice showed some degree of tumor 
regrowth. The median time to tumor progression was 
18 days for untreated, 22 days for 131I--treated, 27 days 
for GEM-treated, and—remarkably—45 days for dual-
therapy-treated mice.
DISCUSSION
Clinically, NIS-mediated radioiodide transport 
has been the centerpiece of diagnostic tests and ablative 
interventions in well-differentiated thyroid cancers for over 
65 years [5, 25, 26]. 131I- treatment is well tolerated, with 
only a few minor side effects [27, 28]. Therefore, it would 
be highly desirable to extend this therapeutic approach 
to NIS-expressing breast cancers [10, 11, 29]. It should 
be emphasized that the covalent incorporation of I- into 
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Figure 2: Radioiodide uptake in MDA-MB-231Br-NIL MFP and BCBM xenografts. A. Tissue biodistribution of 40 µCi 123I- 
i.v. at 2, 4, and 6 hours in mice bearing NIS-expressing MDA-MB-231Br-NIL MFP xenografts. Data represent the mean ± SD of 123I- uptake 
expressed as the percentage of the injected dose per tissue or organ (% ID/g). MFP tumors show peak accumulation of 16.8 ± 8.2 %ID/g 
at 2 hours decreasing to about half at 6 hours and exceeding the stomach at the earlier timepoints. B. Radioiodide uptake in brain 1 hour 
post-injection of 123I- demonstrates that brains with tumors take up 13.6 times more 123I- than normal brain tissue (n = 3). C. Immunoblot of 
NIS expression in MFP and BCBM xenografts shows a predominant band corresponding to the mature polypeptide and a band that migrates 
faster, corresponding to the partially glycosylated polypeptide. Immunohistochemical analysis of NIS expression in MFP and BCBM 
xenografts on day 11 post-implantation. D. Immunoblot of NIS expression in human primary triple negative breast cancer [TNBC] (*BC), 
and of a protein lysate (2 µg) obtained from MDCK transfected with hNIS used as a positive control showing the same electrophoretical 
pattern. This same tumor was minced in RPMI tissue culture and implanted into the MFP in a NOD SCID mouse to generate a patient-
derived orthotopic xenograft (PDOX). Comparable NIS immunoreactivity is observed in the human TNBC and corresponding PDOX. 
E. NIS expression was also assessed by IHC on tissue sections of a TNBC BCBM patient is shown.
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thyroglobulin (i.e., I- organification), which occurs in the 
normal thyroid, is not required for NIS-mediated radioiodide 
therapy to be effective. This is clearly demonstrated by the 
fact that NIS-mediated radioiodide therapy is remarkably 
successful in treating thyroid cancer metastases, even though 
these metastases lack the microscopic architecture of the 
thyroid and therefore do not “trap” organified radioiodide the 
way the healthy thyroid gland does. Moreover, the ablative 
effect of radioiodide has been reported in multiple preclinical 
studies of cancers that do not organify I- [30–32].
The well-known bystander effect of 131I- (i.e., 
its ability to ablate non-NIS-expressing cells by being 
accumulated by surrounding cells) has been demonstrated 
in NIS gene transfer experiments in various cell lines 
[31, 33, 34]. 131I- has been shown to have a greater 
ablative effect in cells organized into spheroids than 
in the same cells grown in monolayers, suggesting that 
a 3-dimensional arrangement allows cells to be within 
the field of radiation of other cells that concentrate 131I-, 
thereby magnifying the effect of 131I-[35, 36] .
Systemic therapies have decreased the rate of distant 
metastases in breast cancer and have brought to the fore 
the daunting challenges of treating brain metastases 
[1, 37, 38]. One central obstacle in treating BCBMs is 
that it is difficult for drugs to cross the BBB. Here, we 
tested a novel strategy combining the radiosensitizing 
properties of GEM and the radioablative effects of 131I- 
in NIS-expressing breast cancer cells. This strategy was 
based on the observation that human BCBMs express 
NIS endogenously: 75% of 28 archival tissues showed 
NIS protein expression, and 24% evinced focal plasma 
membrane staining [10]. These striking findings provided 
the rationale for the translational studies reported here.
BCBMs were generated with a line of braintropic NIS-
transduced cells whose proliferation was inhibited in vitro 
by GEM and by 131I- [Figure 1D and 1E]. In experimental 
CNS metastases, tumor size was decreased notably by the 
combined GEM/131I- treatment. This dual therapy elicited 
a better response than either agent alone, and its effect 
exceeded the sum of the effects of 131I- alone and GEM 
alone [Figure 6]. The magnitude of the response attests to 
the radiosensitizing effect of GEM on tumor cells that either 
actively accumulate 131I- (because they express NIS) or are 
ablated by NIS-mediated 131I- accumulation in neighboring 
cells (i.e., the bystander effect). This point is further 
illustrated by the results with low GEM dosing. GEM alone 
caused regression in 17% of tumors and stable disease in an 
additional 17%, whereas co-administration of GEM and 131I- 
increased the fraction of mice exhibiting tumor regression to 
57% (3.3 times greater) [Figure 6A and 6B]. Moreover, time 
to progression was nearly thrice as long in mice treated with 
high-dose GEM/131I- as in controls [Figure 7].
Figure 3: Effects of gemcitabine, 131I-, and combination treatment on MDA-MB-231Br –NIL MFP tumors. MFP xenograft 
tumors grew over the course of a 50-day period without treatment (Saline, blue solid line), whereas growth was inhibited in tumors treated 
with GEM (58 mg/Kg x4, red line) or 1 mCi 131I- (black line). Dual therapy, GEM 58 mg /kg × 4) plus 1 mCi 131I-, induced greater tumor 
regression (green line). Each data point represents the average of results from at least five mice and the corresponding SEM.
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The bystander effect is likely to have occurred in 
our BCBM model, given that only ~20% of the BCBMs 
expressed NIS strongly. In addition, co-administration of 
a radiosensitizing drug such as GEM sensitized cells to a 
dose of radiation that alone is not therapeutically effective. 
Tissue radiosensitivity depends on many factors, including 
Figure 4: Effects of gemcitabine, 131I-, and combination treatment on MDA-MB-231Br –NIL BCBM. A–D. Mice were 
injected into the right cerebral cortex with 0.2 × 106 cells. Tumor BLI was monitored bi-weekly starting on day 7. Animals with tumors showing 
exponential growth by day 10 (baseline) were randomly assigned to different treatment groups: [A] saline solution alone (dotted arrows); [B] 
131I- 1mCi (black arrow) on day 11 and saline other days; [C] GEM 58 mg/Kg (gray arrows) on days 10, 13, 16, 19; [D] dual therapy: GEM on 
days 10,13,16,19 and 131I- (black arrow) on day 11. Pseudo-color BLI images show a representative animal from each group.
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radiation dose, duration of exposure, and the timing of 
radiation [39]. The low dose GEM approach was based on 
the clinical practice of reducing the dose of GEM when 
given concurrently during radiation therapy [40]. For our 
experiments, a GEM dose that inhibited tumor growth 
without inducing tumor regression was selected. GEM is a 
pyrimidine analogue that is phosphorylated intracellularly. 
Its major metabolite, GEM triphosphate, is competitively 
incorporated into DNA, impairing DNA synthesis and 
thereby causing S-phase cell cycle arrest and depletion 
of the dATP pools [39]. GEM does not significantly bind 
to plasma proteins; rather, it enters cells by facilitated 
diffusion. It has been reported that the drug may be 
preferentially concentrated in brain metastases rather than 
in normal brain tissue [41]. The effect of GEM is greatest 
when cells are exposed to relatively low concentrations 
for at least 24 hours before irradiation, allowing sufficient 
time for the cells to redistribute into early S-phase. Entry 
into S-phase and depletion of endogenous dATP pools are 
critical conditions for radiosensitization of tumor cells. It 
was for this reason that 131I- was administered 24 hours 
after the first dose of GEM.
Microscopic analysis provided insights into the 
variability of NIS expression in MFP and brain tumors. 
Tumors harvested from the MFP 12 days after injection 
showed strong NIS expression in the centrally located 
cells and no NIS expression in the more peripheral areas 
[Figure 2C]. Interestingly, NIS expression in BCBMs 
Figure 5: Effectiveness of the dual treatment. Representative photographs of whole-brain coronal sections from mice infused with Evans 
blue prior to sacrifice, highlighting the location of metastases (left). Staining ranged from intensely blue in the larger tumors from sham or 
saline-treated mice A. to smaller 131I-- and GEM-treated tumors B. and C. respectively. Dual therapy resulted in the smallest tumors of all D. 
Accompanying panels show histologic sections stained with anti-NIS antibody (scale bars 100 µm). Saline-treated tumors show NIS membrane 
staining in ~15% of cells, whereas those treated with 131I- at least doubled in size, using the BLI criterion, and <5% of their cells were NIS-positive 
[B]. In GEM-treated tumors that regressed [C], the proportion of NIS-positive cells was similar to that in the control group. In the GEM/131I- group 
[D], tumors were smallest or undetectable; in the tumor shown, which was classified as stable, <5% of the cells were NIS-positive.
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showed immunoreactivity in the intracerebral portion 
of tumors, but sparse immunoreactivity in areas of the 
same tumors located above the surface of the brain. NIS 
and luciferase genes are transcribed as a single transcript; 
therefore, proliferating cell populations in the periphery of 
a tumor, detectable by increasing BLI, may fail to translate 
NIS. These preclinical animal models replicate the NIS 
heterogeneity observed in immunohistochemical studies 
of human BCBMs, where a relatively small proportion of 
cells exhibit strong NIS expression [10]. Our results further 
demonstrate a synergistic effect of low-dose GEM and 131I- 
in MDA-MB-231Br-generated brain metastases. Clinical 
treatment regimens are characteristically multimodal, 
often involving a combination of endocrine or cytotoxic 
agents and external radiation. Synergism between systemic 
treatments, surgery, and breast irradiation is evidenced in 
the decreasing local recurrence rates achieved in patients 
undergoing breast-conserving therapy[42]. NIS protein 
expression is part of the endogenous repertoire of many 
TN breast cancers, including BCBMs [Figure 2E] [12]. We 
showed that this feature is equally well retained in a PDOX 
[Figure 2D], demonstrating feasibility of potential utility 
of such a model in future clinical testing. In summary, our 
findings indicate that the combination of NIS-mediated 131I- 
accumulation and a radiosensitizing drug like GEM may 
prove an effective treatment for patients with BCBMs.
Figure 6: Effects of different treatments on tumor growth. A–B. Tumor response for each animal was classified as growth if BLI 
was at least twice as intense as the baseline, regression if it was half or less as intense, and stable disease if BLI remained within the 2-fold 
parameter on PID25. The percentage of mice in each category is shown in the bar graph. [A] Effects of the low-dose regimens [14.5 mg 
GEM /kg (days 10, 13, 16, 19) and 2 × 0.5 mCi 131I- (days 11 and 18)], with each agent alone or both combined. [B] Effects of the high-dose 
regimens [GEM 58 mg /kg (days 10, 13, 16, 19) and 1 mCi 131I (day 11)], with each agent alone or both combined. C–D. Comparison of 
antitumor activity of low and high dose GEM, 131I, and combination treatment on MDA-MB-23-Br-NIL brain tumors at PID25. Treatments 
and control groups were compared by one way-analysis of variance followed by post hoc comparisons using the Dunnett’s multiple-
comparisons test. Statistics were performed on log-transformed data. The threshold for significance was set at P<0.05. ns P>0.05, * P≤0.05, 
** P≤0.01, *** P≤0.001, **** P≤0.0001.
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MATERIALS AND METHODS
Cell culture
A braintropic clone of the estrogen, progesterone, 
and HER2 receptor-negative human breast cancer 
cell line, MDA-MB-231Br, was generously provided 
by Dr. Toshiyuki Yoneda (University of Texas Health 
Science Center at San Antonio) [43]. The cells were 
not authenticated further. Early passage cells were 
cultured in RPMI 1640 + L-Glutamine (Gibco; Life 
Technologies, Inc., Grand Island, NY) supplemented 
with 10% fetal bovine serum (FBS, Gibco; Life 
Technologies, Inc., Grand Island, NY) and 1% 
penicillin-streptomycin (P/S) solution and incubated at 
37ºC, 5% CO2 atmosphere. Human embryonic kidney 
fibroblast (HEK 293T) cells were grown in Minimum 
Essential Medium (MEM, Invitrogen) supplemented 
with 10% FBS and 1%P/S.
Cell transduction
MDA-MB-231BR cells were stably transduced with 
a lentiviral vector containing NIS linked via a bi-cistronic 
cassette to firefly luciferase 2 (Fluc2) cDNAs, under the 
CMV promoter (NIS-IRES-LUC= NIL). Briefly, viral 
particles were produced by transfecting the CS-CMV-
NIS-IRES-Fluc plasmid together with defective packaging 
constructs (pCMV.R8.2) encoding HIV-1 gag, pol, rev and 
tat and the plasmid (pMD.G) coding for VSVG envelope 
protein into human embryonic kidney fibroblast (HEK 
293T) cells using standard calcium phosphate transfection 
method as previously described [44]. After transduction, 
single cell clones were isolated by limiting dilution and 
characterized for luciferase expression and I- uptake 
activity.
In vitro bioluminescence imaging (BLI)
Cells were serially diluted from 100,000 to 25 
cells in complete media in 48-well plates and incubated 
overnight at 37ºC. D-Luciferin Firefly potassium salt 
(Biosynth International Inc, Itasca, IL) was added to 
each well (150 µg/ml final) 5–10 min before imaging 
with a Xenogen IVIS-100 imaging system (Caliper Life 
Sciences, Hopkinton, MA). Exposure time was set to 30-
60 sec/plate. Regions of interest (ROI) were drawn around 
each well and bioluminescent intensity quantified in 
photons per second using Living Image software (Caliper 
Life Sciences, Hopkinton, MA).
In vitro uptake studies
Cell NIS activity was determined with 99m TcO4 at 
steady-state conditions as described by Weiss et al. [45]. 
In brief, 1 × 105 cells were seeded on 24-well plates and 
left to attach overnight at 37ºC. Uptake was initiated by 
incubating cells for 1 hour at 37ºC with HBSS buffer 
containing 10 mM Hepes (pH 7.3), 10 µM NaI and 0.1 
µCi Na99mTcO4 per mL. Cells were then washed twice with 
Figure 7: Dual therapy delays tumor progression. Kaplan-Meier survival analysis is shown using median survival time for each 
treatment group or the time required to achieve 5 times the bioluminescence compared to its respective baseline on PID10. Sham or saline-
treated [gray], 131I- [blue], GEM [green], GEM + 131I- [red]. The threshold for significance was set at p < 0.05.
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ice-cold HBSS-Hepes buffer and lysed with RIPA buffer 
for 20 minutes on ice. Radioactivity of protein lysates was 
measured in a Cobra II gamma-counter (Packard Cobra, 
Packard Instrument Inc., Meriden, CT) and normalized 
to protein content measured by BCA assay (Thermo 
Scientific-Pierce, Rockford, IL). Each experiment was 
carried out in triplicate, in parallel with 100 µM KClO4 
for inhibition of NIS activity.
Cell proliferation assay
Cells were harvested and seeded at a density of 
500 cells/well in 96-well plates, incubated for 24 hours at 
37°C, and then GEM (0.0001 to 1000 µM final) was added 
to each well. After 48 hours, cell viability was measured 
by the MTS assay according to the manufacturer’s 
recommendations (CellTiter 96AQueous One Solution 
Reagent, Promega, Madison, WI). Specific absorbance 
was measured at 490 nm and background at 630 nm with 
a 96-well plate reader (Biotek power wave XS, Biotek 
Instrument Inc. Wonooski, VT). Each concentration of 
GEM was tested in six wells and repeated in at least three 
independent experiments. The percentage of untreated or 
control cells surviving, was considered as 100. Percent cell 
survival was calculated using the following equation: 100* 
(A490 - A630 treated)/A490 - A630 control).
Clonogenic cell survival assay
Cells (7 × 105) were seeded on T25 flasks, and 
allowed to attach overnight. The next day cells were 
washed twice with warm HBSS and incubated in HBSS 
supplemented with 10 mM Hepes (pH 7.3), 10 µM Na131I 
containing either 0, 4, 20, 40, 200, or 400 µCi 131I- for 
7 hours. Following incubation, cells were washed with 
HBSS-Hepes buffer, harvested, and reseeded at desired 
densities (2, 5, 10, 20, 50 and 100 cells/cm2) in six-well 
plates. All incubations were done at 37ºC. Once colonies 
developed, cells were fixed with methanol and stained 
with crystal violet (0.5% w/v methanol). Only colonies 
containing more than 50 cells were scored. The surviving 
fractions (SF) were calculated as: (mean plating efficiency 
of treated cells/mean plating efficiency of control 
cells)*100%, where the plating efficiency (PE) is the 
number of colonies divided by the number of cells seeded.
Animal experiments
Mouse experiments were conducted and approved 
by the Administrative Panel on Laboratory Animal Care 
(APLAC) at Stanford University. Six to eight week-
old female, athymic, nude mice (Ncr nu/nu) (Taconics, 
Hudson, NY) were used. Mice were anesthesized for 
imaging sessions and all procedures carried out with 
continuous 3% isofluorane (Aerrane, Baxter Healthcare 
Corp, Deerfield, IL), except for stereotactic tumor cell 
injections, which were performed using intraperitoneal 
ketamine/xylazine cocktail (100/10 mg/kg).
To generate mammary fat pad (MFP) xenografts, 
cells were harvested at 80% confluence, resuspended in 
HBSS and 1x106 cells injected with an equal volume of 
Matrigel (BD Biosciences, San Jose, CA). For the brain 
metastases model, anesthetized mice were secured onto 
a stereotactic frame (Kopf Instruments, Tujunga, CA). A 
0.7-mm burr hole was drilled via a scalp incision overlying 
the right cerebral hemisphere, 2 mm lateral and 1 mm 
superior to the bregma using a high-speed micro drill (Fine 
Science Tools, Foster City, CA). After dural penetration, 
a 2-µL suspension containing low-passage 2 × 105 MDA-
MB-231Br-NIL cells was injected at a depth of 2.5 mm 
over a four-minute period through a 26-G needle attached 
to a 10-µL microinjector syringe (Hamilton Co, Reno, 
NV). The needle was then retracted 0.5 mm/min, the burr 
hole sealed with bone wax (World Precision Instrument, 
Inc., Sarasota, FL), and the scalp closed using 5-0 vicryl 
sutures (Ethicon, Inc, Somerville, NJ).
In vivo bioluminescence imaging
Tumor growth and response to treatment were 
assessed longitudinally by in vivo BLI with 150 mg/
kg D-Luciferin injected intraperitoneally (i.p). Imaging 
was initiated within five minutes and sequential images 
were acquired at 3-minute intervals until peak BLI signal 
was reached for each animal. In the mice with BCBM, 
treatment effect was assessed by calculating changes in 
tumor bioluminescence at each time-point relative to the 
BLI intensity recorded for that mouse at baseline (PID10).
In vivo iodide uptake experiments
Two weeks after inoculation, mice bearing MFP 
tumor xenografts were injected with 40 µCi (1.48 MBq) 
of Na123I in 0.9% saline solution iv. Mice (n = 5) were 
sacrificed at 2, 4, 6, and 24 hours post-injection. Blood, 
tumors, and organs were harvested, and radioactivity 
was counted using a Cobra II gamma-counter (Packard 
BioScience). Organ uptake was calculated as the 
percentage of the injected dose per gram of tissue (%ID/g).
Treatment of mammary fat pad xenografts
Dosing experiments for GEM and 131I- were 
carried out in MFP xenografts. Mice were implanted 
with methimazole 0.25 mg/21 day release pellet and 
L-thyroxine 0.1 mg/21-day release pellet (Innovative 
Research of America, Inc, Sarasota, FL). In addition 10 
mg of methimazole were added to 5 ml sterile drinking 
water and mice were injected with T3 47.6 ng/ 20 μl 
i.p. daily. GEM hydrochloride (Sagent Pharmaceutical 
Inc., Schaumburg, IL/Hospira Inc., Lake Forest, IL) was 
administered 58 mg/kg (174 mg/m2) i.p. every 3 days x 4 
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[46]. 131I- therapy was given as 2 doses of 0.5 mCi each 7 
days apart (PID11 and PID18).
Treatment of brain metastases
Two dosing schemes were selected, one replicating 
the MFP experiments and a second using one-fourth the 
dose of GEM to minimize drug therapeutic effect. Mice 
with exponentially growing BCBM on PID10 were 
randomly assigned to one of four treatment groups (n ≥9 
per group): [A] saline sham (0.9% NaCl), [B1] GEM 14.5 
mg/Kg or [B2] 58 mg/kg i.p. every 3 days × 4 (days 10, 
13, 16 and 19), and [C1] 1mCi 131I- on PID11 or [C2] 0.5 
mCi 131I- on PID11 and 18. For the GEM/131I- combination 
treatments, mice received [D1] 14.5 mg/kg GEM + 2 × 0.5 
mCi 131I- or [D2] GEM 58 mg/Kg × 4 + 1 mCi 131I-. Sham 
and GEM mice received saline instead of 131I- while sham 
and 131I- groups received saline instead of GEM. Mice in 
experiments corresponding to low-dose GEM and divided 
doses of 131I- were sacrificed on PID25.
To suppress thyroidal radioiodide uptake and 
intrathyroidal organification of I-, all mice received daily 
L-thyroxine (100 µg/kg; Sigma-Aldrich, St. Louis, MO), 
triiodo-L-thyronine 2.38 µg/kg (Sigma-Aldrich, St. Louis, 
MO), and methimazole 500 µg/kg (Par Pharmaceutical Inc., 
Woodcliff Lake, NJ) starting the day of cell inoculation 
through completion of treatment. Mice underwent BLI 
imaging twice weekly to assess tumor response and were 
humanely euthanized if they experienced weight loss in 
excess of 20% of pre-treatment weight or when moribund. 
In order to investigate maximal tumor response and time to 
tumor regrowth or progression, mice were monitored for 
up to 8 weeks or physical decline, whichever came first. 
In experiments using low-dose GEM regimens, mice were 
sacrificed at the time of BLI nadir (PID25). Tumor response 
was classified as growth, stability, or regression based on a 
2-fold change in BLI. The histological appearance and NIS 
immunohistochemical profile of tumors at this timepoint 
was analyzed.
Patient-derived orthotopic xenografts (PDOX)
This procedure was approved by the Stanford 
University’s Research Compliance Office on Human 
Subjects Research and IRB, as well as Stanford’s 
Administrative Panel on Laboratory Animal Care (APLAC). 
Informed written consent was obtained from the patient and 
fresh tumor tissue was taken at the time of surgical excision. 
The sample was placed in ice cold RPMI 1640 medium 
supplemented with penicillin/streptomycin and 10% heat-
inactivated FBS (Invitrogen-Life Technologies, Carlsbad, 
CA, USA) as previously described by our group [47]. One 
to two mm fragments were mixed with LDEV-free Matrigel 
(BD Biosciences, San Jose, CA, USA) and orthotopically 
implanted into the MFPs of 5 female NOD SCID mice 
(NOD. CB17-Prkdcscid/J, Jackson Laboratory West, 
Sacramento, CA, USA). Mice were housed in a pathogen-
free animal environment. Once established, PDOX tumors 
were expanded by passaging from mouse to mouse. After 
a second passage, one PDOX tumor was fixed in formalin 
and embedded in paraffin for immunohistochemical studies.
Immunohistochemistry
Five-micron formalin-fixed, paraffin-embedded 
tissue sections were deparaffinized, rehydrated through 
graded alcohol changes and then subjected to heat-
induced epitope retrieval in 0.01 M citrate buffer 
(pH 6.0) for 30 minutes at a sub-boiling temperature. 
Immunohistochemistry (IHC) staining was carried with 
biotin-free catalyzed signal amplification kit (CSA II; 
DAKO, Carpinteria, CA). Slides were counterstained 
with hematoxylin before mounting. Appropriate positive 
(thyroid Graves’ disease) and negative (no primary 
antibody) controls were included with each IHC run. 
NIS expression was determined using a custom affinity-
purified polyclonal anti-human NIS antibody (AnaSpec, 
Fremont, CA) generated against the last 13 amino acids of 
the carboxy-terminal end of the protein.
Data analysis
Statistics were performed using GraphPad Prism 
version 6.00 for Mac OSX (GraphPad Software, La Jolla 
California USA).
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